IP Library Granted Patent US 9,724,436
Granted Patent B2
US 9,724,436 · App. 13/578,578 · Granted Aug 8, 2017

Alpha-emitting complexes

Inventor: Thomas Ramdahl (Eiksmarka, NO)
Assignee: BAYER AS
A61K51/0478A61K51/1045A61K51/1051A61K51/1072A61K51/1093
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,724,436
App. No.
13/578,578
Granted
Aug 8, 2017
Kind
B2
Abstract

The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

Claims (11)

1. A tissue-targeting complex consisting of

a tissue targeting moiety selected from antibodies, antibody constructs, fragments of antibodies, constructs of fragments or a mixture thereof, peptide, amino acid, steroidal or non-steroidal hormone, folate, estrogen, testosterone or biotin,

an octadentate hydroxypyridinone-containing ligand, and

an ion of an alpha-emitting 227-thorium radionuclide,

wherein said octadentate ligand is selected from the group consisting of formula VI and VII

a coupling moiety which links said formula VI or said formula VII to said tissue targeting moiety.

2. The tissue targeting complex of claim 1 , wherein said tissue targeting moiety is an antibody.

3. A method of treatment of a human or non-human animal body having a hyperplastic or a neoplastic disease, comprising administration of at least one tissue-targeting complex to said human or non-human animal body, wherein said tissue-targeting complex is a complex as claimed in claim 1 .

4. A pharmaceutical composition comprising a tissue-targeting complex together with at least one pharmaceutical carrier or excipient, wherein said tissue-targeting complex is a complex as claimed in claim 1 .

5. A method of treatment of a human or non-human animal body having a hyperplastic or a neoplastic disease, comprising administration of at least one tissue-targeting complex to said human or non-human animal body, wherein said tissue-targeting complex is a complex as claimed in claim 2 .

6. A pharmaceutical composition comprising a tissue-targeting complex together with at least one pharmaceutical carrier or excipient, wherein said tissue-targeting complex is a complex as claimed in claim 2 .

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Apr 7, 2017
From: ALGETA ASA; BAYER AS
To: BAYER AS
Reel/Frame 041927/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2012
From: RAMDAHL, THOMAS
To: ALGETA ASA
Reel/Frame 029102/0657 →
Priority Claims (1)
GB 1002508.8 · Feb 12, 2010 · national
Continuity (1)
Related Publication 20130183235A1 · Jul 18, 2013